Advyzon Investment Management LLC Buys New Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Advyzon Investment Management LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 4,523 shares of the biopharmaceutical company’s stock, valued at approximately $418,000.

A number of other hedge funds have also recently modified their holdings of GILD. AMF Tjanstepension AB grew its position in shares of Gilead Sciences by 14.7% in the 3rd quarter. AMF Tjanstepension AB now owns 400,819 shares of the biopharmaceutical company’s stock valued at $33,645,000 after buying an additional 51,390 shares during the last quarter. Swedbank AB boosted its stake in Gilead Sciences by 10.2% during the 3rd quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company’s stock worth $171,672,000 after purchasing an additional 189,622 shares during the period. nVerses Capital LLC acquired a new stake in Gilead Sciences during the 3rd quarter worth $25,000. Foundations Investment Advisors LLC boosted its stake in Gilead Sciences by 21.1% during the 3rd quarter. Foundations Investment Advisors LLC now owns 49,665 shares of the biopharmaceutical company’s stock worth $4,164,000 after purchasing an additional 8,662 shares during the period. Finally, Signaturefd LLC boosted its stake in Gilead Sciences by 12.1% during the 3rd quarter. Signaturefd LLC now owns 21,000 shares of the biopharmaceutical company’s stock worth $1,761,000 after purchasing an additional 2,271 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

GILD has been the subject of a number of recent research reports. Citigroup initiated coverage on shares of Gilead Sciences in a research note on Thursday, November 14th. They set a “buy” rating and a $125.00 price target for the company. Wolfe Research initiated coverage on shares of Gilead Sciences in a research note on Friday, November 15th. They set an “outperform” rating and a $110.00 price target for the company. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Royal Bank of Canada raised their target price on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a research note on Wednesday, February 12th. Finally, Bank of America restated a “buy” rating and issued a $109.00 target price on shares of Gilead Sciences in a research note on Tuesday, December 10th. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $102.08.

Gilead Sciences Stock Performance

NASDAQ:GILD opened at $107.65 on Thursday. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The firm has a 50-day moving average price of $94.70 and a two-hundred day moving average price of $88.23. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $107.81. The company has a market capitalization of $134.16 billion, a P/E ratio of 290.95, a price-to-earnings-growth ratio of 0.87 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, research analysts expect that Gilead Sciences, Inc. will post 7.94 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be issued a dividend of $0.79 per share. The ex-dividend date is Friday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.94%. Gilead Sciences’s payout ratio is 832.43%.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 164,211 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the sale, the insider now directly owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. This trade represents a 67.02 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 248,645 shares of Gilead Sciences stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the transaction, the chief financial officer now directly owns 138,919 shares in the company, valued at approximately $12,886,126.44. This trade represents a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 713,000 shares of company stock worth $67,945,181 over the last ninety days. 0.29% of the stock is currently owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.